Canaccord Genuity Reiterates a 'Buy' on AngioDynamics (ANGO); Good Start for New CEO
Tweet
Share
E-mailGet Alerts ANGO Hot Sheet
Price: $15.85 +1.21%
Rating Summary:
8 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on AngioDynamics (NASDAQ: ANGO) price target raised to $18.50.
Canaccord analyst, Jason R. Mills, said, "FQ1 exceeded our expectations, kicking off the tenure of new CEO Joe DeVivo. We believe investors should aggressively accumulate ANGO shares at current levels, owing to a very favorable risk/reward value proposition, in our view. Mr. DeVivo offered his initial vision for the company, conveying a clear understanding of the key issues and important tenets to set ANGO on an upward growth trajectory again. Based on a review of his experience and our due diligence, we have confidence Mr. DeVivo will unlock tremendous shareholder value at ANGO."
"We increase our forward estimates. ANGO maintained F12 guidance at $217-
225M/$0.41-0.49. We believe N/K and venous ablation offer the best upside
potential in F2012."
For more ratings news on AngioDynamics click here and for the rating history of AngioDynamics click here.
Shares of AngioDynamics closed at $14.27 yesterday.
Canaccord analyst, Jason R. Mills, said, "FQ1 exceeded our expectations, kicking off the tenure of new CEO Joe DeVivo. We believe investors should aggressively accumulate ANGO shares at current levels, owing to a very favorable risk/reward value proposition, in our view. Mr. DeVivo offered his initial vision for the company, conveying a clear understanding of the key issues and important tenets to set ANGO on an upward growth trajectory again. Based on a review of his experience and our due diligence, we have confidence Mr. DeVivo will unlock tremendous shareholder value at ANGO."
"We increase our forward estimates. ANGO maintained F12 guidance at $217-
225M/$0.41-0.49. We believe N/K and venous ablation offer the best upside
potential in F2012."
For more ratings news on AngioDynamics click here and for the rating history of AngioDynamics click here.
Shares of AngioDynamics closed at $14.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
- Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
